Veterinary Medicines

Versican Plus DP lyophilisate and solvent for suspension for injection for dogs

Authorised
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
  • Canine distemper virus, strain CDV Bio 11/A, Live
Download as PDF

Product identification

Medicine name:
Versican Plus DP lyophilisate and solvent for suspension for injection for dogs
Versican Plus DP Lyofilisaat en oplosmiddel voor suspensie voor injectie
Versican Plus DP Lyophilisat et solvant pour suspension injectable
Versican Plus DP Lyophilisat und Lösungsmittel zur Herstellung einer Injektionssuspension
Active substance:
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
  • Canine distemper virus, strain CDV Bio 11/A, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parvovirus, type 2b, strain CPV-2b Bio 12/B, Live
    19952.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain CDV Bio 11/A, Live
    1258.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD03
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Belgium
Available in:
  • Belgium
Package description:
  • (ID2) 50 Dose; 50 millilitre(s): Box (plastics) with 50 Vial (glass) each with 1 Dose and 50 Vial (glass) each with 1 millilitre(s)
  • (ID1) 25 Dose; 25 millilitre(s): Box (plastics) with 25 Vial (glass) each with 1 Dose and 25 Vial (glass) each with 1 millilitre(s)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Bioveta a.s.
Responsible authority:
  • Federal Agency For Medicines And Health Products
Authorisation number:
  • BE-V496560
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0266/001
Concerned member states:
  • Belgium
  • Bulgaria
  • Cyprus
  • Greece
  • Hungary
  • Italy
  • Lithuania
  • Luxembourg
  • Netherlands
  • Poland
  • Portugal
  • Romania
  • Spain
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 17/08/2025
Download
French (PDF)
Published on: 17/08/2025
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 17/08/2025
Download
French (PDF)
Published on: 17/08/2025
Download
German (PDF)
Published on: 17/08/2025
Download

Combined File of all Documents

English (PDF)
Published on: 24/05/2023
Download

Labelling

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 17/08/2025
Download
French (PDF)
Published on: 17/08/2025
Download
German (PDF)
Published on: 17/08/2025
Download

2613562-paren-20251101.pdf

English (PDF)
Published on: 27/11/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."